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ABSTRACT
Pseudohypoparathyroidism type 1A (PHP1A), pseudoPHP (PPHP), and PHP type 1B (PHP1B) are caused bymaternal and paternalGNASmutations
and abnormalmethylation atmaternalGNAS promoter(s), respectively. Adult PHP1A patients are reportedly obese and short, whereasmost PPHP
patients are born small. In addition to parathyroid hormone (PTH) resistance, PHP1A and PHP1B patientsmay display early-onset obesity. Because
early-onset and severe obesity and short stature are daily burdens for PHP1A patients, we aimed at improving knowledge on the contribution of
the GNAS transcripts to fetal and postnatal growth and fat storage. Through an international collaboration, we collected growth and weight data
from birth until adulthood for 306 PHP1A/PPHP and 220 PHP1B patients. PHP1A/PPHP patients were smaller at birth than healthy controls,
especially PPHP (length Z-score: PHP1A –1.1 1.8; PPHP –3.0 1.5). Short stature is observed in 64% and 59% of adult PHP1A and PPHP patients.
PHP1Bpatients displayedearly postnatal overgrowth (heightZ-score at 1 year: 2.2 1.3 and1.3 1.5 in autosomal dominant and sporadic PHP1B)
followed by a gradual decrease in growth velocity resulting in normal adult height (Z-score for both: –0.4 1.1). Early-onset obesity characterizes
GNAS alterations and is associated with signiﬁcant overweight and obesity in adults (bodey mass index [BMI] Z-score: 1.4 2.6, 2.1 2.0, and
1.4 1.9 in PPHP, PHP1A, and PHP1B, respectively), indicating that reduced Gsa expression is a contributing factor. The growth impairment in
PHP1A/PPHPmay be due to Gsa haploinsufﬁciency in the growth plates; the paternal XLas transcript likely contributes to prenatal growth; for all
disease variants, a reducedpubertal growth spurtmaybedue to acceleratedgrowthplate closure. Consequently, early diagnosis and close follow-
up is needed in patients with GNAS defects to screen and intervene in case of early-onset obesity and decreased growth velocity. © 2018 The
Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research
(ASBMR).
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Introduction
Pseudohypoparathyroidism (PHP) was deﬁned initially byFuller Albright as the resistance to the parathyroid hormone
(PTH) characterized by hypocalcemia and hyperphosphatemia
in association with different features of Albright hereditary
osteodystrophy (AHO), including stocky build, brachydactyly,
and short stature. These patients often present with additional
features such as early-onset obesity, subcutaneous ossiﬁcations,
neurocognitive deﬁciency, and resistance to other hormones
that mediate their actions through the alpha-subunit of the
stimulatory G protein (Gsa), such as thyroid-stimulating
hormone (TSH).(1,2) Differently, pseudoPHP (PPHP) is character-
ized in most patients by physical symptoms of AHO yet no
resistance to PTH or TSH. Binding of these hormones to their
receptors promotes the coupling to the G protein and cAMP
generation by adenylyl cyclase. Gsa is encoded by exons 1-13 of
GNAS, part of a complex imprinted locus on chromosome
20q13.3. GNAS encodes at least four additional transcripts using
alternative ﬁrst exons and their promoters that undergo parent-
speciﬁc methylation. These include NESP55 (NeuroEndocrine
Secretory Protein 55), derived from the nonmethylatedmaternal
allele, whereas XLas (the eXtra Large variant of Gsa), the A/B
transcript, and an antisense (AS) transcript are transcribed from
the nonmethylated paternal GNAS allele(3) (Fig. 1). Although Gsa
is derived in most tissues from both parental alleles, its
expression from the paternal GNAS allele can be reduced or
abolished in some tissues, such as renal proximal tubules, brown
adipose tissue, pituitary, gonads, thyroid, and hypothalamus
through an as yet undeﬁned tissue-speciﬁc silencing
mechanism.(4,5) Maternal loss-of-function mutations at GNAS
exons 1-13 cause PHP type 1A (PHP1A). Interestingly, the same
or similar mutations on the paternal allele cause PPHP.(6)
In contrast, PHP type 1B (PHP1B) encompasses patients
with methylation defects at one or more GNAS promoters.(7)
About 20% of PHP1B patients present with an autosomal
form of the disease (AD-PHP1B) characterized by loss of
methylation restricted to the maternal exon A/B DMR (GNAS
A/B:TSS-DMR).(8) Most of these patients display a maternal
3-kb microdeletion within STX16, located approximately
220 kb upstream of GNAS.(8) Patients with the sporadic
form of PHP1B (spor-PHP1B)—about 70% of all PHP1B
patients—present with abnormal maternal methylation
involving at least one GNAS DMR in addition to the GNAS
A/B:TSS-DMR.(7,8) The mechanisms underlying these methyl-
ation changes have not yet been deﬁned. Lastly, approxi-
mately 10% of all spor-PHP1B cases are caused by paternal
uniparental isodisomy of chromosome 20q [iUPD(20q)pat],
which includes the GNAS locus.(9) Resistance to PTH is the
most prominent ﬁnding in patients affected by PHP1B, but
mild resistance to TSH occurs frequently.(10)
PHP may easily be confused with other diseases because of
clinical, biochemical, and/or molecular overlap. We note that a
recently proposed alternate classiﬁcation uses the term
“inactivating PTH/PTHrP Signaling Disorder”(11) to describe
GNAS loss-of-function mutations. PHP1A and PPHP, which
involve mutations of either the maternal or the paternal allele,
are referred to as iPPSD2, and PHP1B variants caused by GNAS
methylation defects are referred to as iPPSD3 (defects upstream
of Gsa, eg, inactivating PTH1R mutations, are referred to as
iPPSD, and mutations in PRKAR1A, PDE4D, and PDE3A are
referred to as iPPSD4, iPPSD5, and iPPSD6, respectively).
Fig. 1. Schematic drawing of the GNAS locus. The imprinted human GNAS locus (not to scale, Hg19-chr20:57,414,795-57,486,250) and the STX16 gene
(Hg19-chr20:57,226,309-57,254,5812) on chromosome 20. The centromeric/telomeric (cen/tel) orientation of the chromosome is indicated. Boxes
indicate coding exons. Black boxes: transcripts expressed from both parental allele; gray boxes: transcripts expressed only from the paternal allele; white
box: transcript expressed predominantly from the maternal allele. Asterisks indicate the differentially methylated regions. Arrows: transcription
(direction and parental origin). Transcripts are drawn above (mat: maternal) or below (pat: paternal) theGNAS locus and the STX16 gene; for clarity, the N1
exon that is located between exon 3 and 4 of GNAS, and is alternatively spliced, has not been included in this scheme. Sense transcripts (NESP, XLas, A/B,
and Gsa) have their own ﬁrst exon and share GNAS exons 2 to 13.
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It hasbeen frequently reported that patients affectedbyPHP1A
andPPHPhave adult heights that are approximately –2.5 and –2.3
SD, respectively, below average;(12,13) growth delay is already
present at birth in both diseases, particularly in PPHP patients.(14)
By contrast, ﬁnal adult heights of AD-PHP1B and spor-PHP1B
patients are described as “normal” in most reports despite recent
descriptions of enhanced fetal growth(15) and case reports of
postnatal overgrowth(16,17) (a summary of the evidence available
in the literature for pre- and postnatal growth in PHP1A, PPHP,
and PHP1B is provided in Supplemental Table S1). Obesity is well
known to be associatedwith PHP1A as exempliﬁed by the largest
study to date conducted in adults affected by this disorder,
showing an average body mass index (BMI) Z-score of 1.7 0.2
with two-thirds of the patientsmeeting the criteria for obesity.(13)
In addition, early-onset obesity has been observed in case reports
and small series of patients with PHP1B.(16,17)
Besides fetal growth data, longitudinal trajectories of growth
and weight and their determinants are currently unknown for
patients affected by the different PHP variants, and ﬁnal heights
and BMI have not been systematically evaluated in either
disorder. Obesity and short stature represent heavy burdens in
the daily life for many of these patients. Therefore, the goals of
our study were to: 1) determine the longitudinal pattern of
growth and weight gain for large cohorts of patients affected by
PHP1A and PPHP (carrying a GNAS loss-of-function mutation)
and by AD-PHP1B and spor-PHP1B (carrying aGNASmethylation
defect); 2) determine adult height, weight, and BMI of patients
affected by these disorders; and 3) enhance our understanding
of the mechanisms and the roles of the different GNAS-derived
transcripts in fetal and postnatal growth and weight gain. We
strongly believe that a thorough analysis and understanding of
these exemplary rare diseases will contribute to better
management and care of affected patients and will help
generate hypotheses regarding the underlying mechanisms.
Materials and Methods
Patients
We collected the GNAS molecular defect, gestational age,
length/height, and weight parameters from birth until the most
recent available data or the age of 18 years (longitudinal data) of
patients affected with a documented molecular defect at the
GNAS locus, hence a diagnosis of either PHP1A, PPHP, AD-
PHP1B, or spor-PHP1B. We gathered the data available at the
following time points: birth, 0.5, 1, 1.5, 2, 3, 6, 8, 10, 12, 14, 16, and
18 years. Data were obtained from patients in France, Spain,
Italy, and USA. Some growth and weight aspects have been
partially reported for a subset of these patients (Supplemental
Table S1). Patients affected with PHP1B due to iUPD(20q)pat
were excluded from the study because the duplication of the
paternal chromosome may affect other genes on chromosome
20q with an unknown impact on growth and weight gain.
Growth and weight data of patients treated with growth
hormone were included only until recombinant human growth
hormone (rhGH) therapy was initiated. Ethnicity and average
measurement per country, per patient, and per age group are
available in Supplemental Table S2. We calculated BMI, using
the formula weight (kg)/height (m)2. Z-scores for length/height,
weight, and BMI were derived from the World Health
Organization (WHO) growth charts.(18) Small for gestational
age (SGA) and macrosomia are deﬁned by Z-scores of birth
weight and/or birth length for gestational age below –1.28 and
above 2.0 (<10th and >97th centile), respectively.(19) When
term was deﬁned in medical ﬁles as “full term,” Z-scores were
calculated using 39 weeks of gestation; however, these patients
were not included in the calculation of mean gestational age.
Short and tall stature are deﬁned by Z-scores of adult height
(measure shown at 18 years in the present report) below –2.0
and above 2.0 (<3rd and >97th centile), respectively. Over-
weight and obesity were deﬁned as BMI above 25 and 30 kg/m2,
respectively. After establishing the diagnosis, patients were
regularly monitored for PTH and TSH resistance; LdS, PK, AR, DT,
ST, AHS, HJ, GM, and AL managed most of the patients.
In the ﬁgures and legends, iPPSD2 refers to patients affected
with a GNAS loss-of-function mutation, whereas iPPSD3 refers to
patients with a GNAS methylation defect.(11) To address
speciﬁcally maternal or paternal GNASmutations or the different
subtypes of methylation defects, the terms of PHP1A, PPHP,
AD-PHP1B, or spor-PHP1B have been preferred.
The study was approved by the Comite Consultatif sur le
Traitement de l’Information en Matiere de Recherche dans le
Domaine de la Sante (CCTIRS, #13-028) under the promotion of
the INSERM (Institut National de la Sante et de la Recherche
Medicale) (#DC-2013-1762). Similarly, institutional review
boards approved the use of data for the study in USA, Italy,
and Spain (Vanderbilt University Medical Center, IRB#130735;
Massachusetts General Hospital, IRB#2001P000648; OSI Araba
University IRB #PI2013214 and PI2017018).
Molecular characterization of the GNAS gene/locus
The diagnosis of PHP1A was based on the presence of PTH
resistance and AHO features associated with maternal loss-of-
function mutations involving GNAS exons 1 to 13 documented
by DNA sequencing. The parental origin of the mutation was
determined by investigating the parents or, in the case of de
novo mutations and if parental DNA was available, through
the cloning of PCR amplicons and the analysis of informative
intragenic polymorphisms that reside on the same allele as the
disease-causing mutation and assigned to one parent. In
some patients for whom it was not possible to determine the
allelic origin through disease transmission or polymorphism
transmission, the GNAS transcripts were ampliﬁed from blood
lymphocytes (GNAS exon A/B to exon 13) as described by Turan
and colleagues.(20) Finally, in a few remaining patients, the
diagnosis of PHP1A was based on the presence of PTH
resistance, AHO features, and a disease-causing GNASmutation.
The diagnosis of PPHP was based on the presence of a GNAS
mutation on the paternal allele and AHO features without
hormonal resistance. In a few PHP1A patients (n¼ 10), the exact
mutation could not be retrieved from medical notes.
To explore the possibility of genotype/phenotype relation-
ships, GNAS variants were divided as follows: 1) variants that
severely impact Gsa function, ie, premature stop codons and
insertions/deletions (indels) leading to a shift in the open
reading frame versus variants predicted to impact Gsa function
less profoundly, ie, amino acid substitutions and in-frame indels
and 2) variants locatedwithinGNAS exon 1 predicted to preserve
the XLas function in affected PHP1A patients versus variants
located within GNAS exons 2-13 predicted to affect the function
of both Gsa and XLas in PHP1A (Fig. 1).
The diagnosis of PHP1B was based on the presence of PTH
resistance without obvious AHO features in association
with abnormal methylation at the GNAS A/B:TSS-DMR alone
or including other GNAS DMRs. Methylation defects were
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documented by pyrosequencing or MS-MLPA, as described.(21)
AD-PHP1B was deﬁned by the association of a methylation
defect restricted to the GNAS A/B:TSS-DMR, the recurrent 3-kb
STX16 deletion, or the 4.4-kb STX16 deletion in one family.
Spor-PHP1Bwas deﬁned by amethylation defect affecting GNAS
A/B:TSS-DMR and at least one otherGNASDMR. In these patients,
iUPD(20q)pat was excluded by showing, through single-
nucleotide polymorphism (SNP) array or microsatellite analysis
of genomic DNA, that the patient is heterozygous throughout
the GNAS/STX16 locus. Patients affected by AD-PHP1B due to
GNAS deletions removing NESP or antisense exons were not
included.
Statistical analysis
Statistical analyses were performed using Prism software 6.0.
Length/height, weight, and BMI at birth, 1 year, 3 years,
10 years, and 18 years are presented as Z-scores (mean SD;
number of independent samples; p value). Longitudinal growth
patterns of patients are presented as a function of age
(mean SD) and are grouped by diseases PHP1A and PPHP
versus AD-PHP1B and spor-PHP1B. When three or fewer values
are available per age group, data are not averaged and thus do
not appear on the ﬁgures.
The one-way ANOVA test followed by a Tukey’s multiple
comparisons test was used to compare the results for different
types of disease variants (alpha¼ 0.05), and t tests were
performed to compare whether data (Z-score) of patients
were signiﬁcantly different from the hypothetical value of zero
(mean of the population) (alpha¼ 0.05). We used the unpaired t
test to compare data between the two subtypes of PHP1B.
Results
Patients
Data were collected from 526 patients affected either by PHP1A,
n¼ 242 (107M, 135 F), PPHP, n¼ 64 (19M, 45 F), AD-PHP1B, n¼ 92
(46M, 46 F), or spor-PHP1B, n¼ 128 (60M, 68 F) (Table 1).
Altogether, 306 patients carry a mutation on their GNAS gene,
whereas 220patients exhibitmethylationdefects at theGNAS locus.
Among the PHP1A and PPHP patients, 66% and 76%,
respectively, carry a mutation that likely impacts Gsa function
severely.GNAS exon 1mutationswere identiﬁed in 19% and 25%
of PHP1A and PPHP patients, respectively. In PHP1A patients, the
different maternal GNAS mutations are not expected to alter
expression or function of the paternal XLas transcript. In PPHP
patients, the paternal exon 1 mutations should not affect XLas
protein (Fig. 1).
Gestational age and birth parameters (Table 1,
Supplemental Table S3, Supplemental Fig. S1)
PHP1A patients
Twenty-one percent (21/99) of the patients affected by PHP1A
were born prematurely, ie, before the 37th week of gestation
(average gestational age: 38.3 2.6 weeks). Compared with
healthy newborns, intrauterine growth was moderately im-
paired for PHP1A patients as the Z-scores for birth length and
birth weight were –1.1 1.8 (n¼ 143) and –0.6 1.6 (n¼ 169),
respectively (p< 0.0001 for both). Thirty-seven percent of the
patients were born small for gestational age (SGA). No
differences were observed when grouping the patients based
on the type of GNASmutations, ie, mutations that are predicted
to impair Gsa function severely or mildly. At birth, PHP1A
patients with mutations involving GNAS exon 1 (n¼ 29) had
slightly lower weight Z-scores compared with PHP1A patients
with mutations in GNAS exons 2-13 (n¼ 135; –1.1 0.9 versus
–0.5 1.8; p¼ 0.0074). Birth length Z-scores of both PHP1A
cohorts were not different (–1.2 0.7 [n¼ 23] versus –1.1 1.9
[n¼ 115]; p¼ 0.7124).
PPHP patients
Data regarding the duration of pregnancy were available for
about half of the PPHP patients (n¼ 34). The mean gestational
age was 37.6 2.5 weeks, which is not different from that of the
PHP1A patients (p¼ 0.2096); approximately one-ﬁfth of the
patients (20%) were born prematurely. Intrauterine growth of
the PPHP cohort was severely altered in comparison to the
reference population, ie, the mean Z-scores for birth length and
weight were –3.0 1.5 (n¼ 38; p< 0.0001) and –2.7 1.3
(n¼ 42; p< 0.0001), respectively. Overall, 95% of the PPHP
patients were SGA at birth. Patients with a mutation involving
GNAS exon 1 were less severely affected than those with a
mutation in GNAS exon 2-13 (birth weight Z-score –1.9 0.9
[n¼ 12] versus –3.0 1.3 [n¼ 29]; p¼ 0.0049).
PHP1B patients
None of the AD-PHP1B patients for whom sufﬁcient information
regarding their pregnancy was available (n¼ 32) were born
prematurely, whereas 12% of the spor-PHP1B cases (8 of 64)
were born before 37weeks of gestation. Among PHP1B patients,
only those affected by AD-PHP1B showed evidence of increased
fetal growth in comparison to healthy controls (birth length
Z-score 0.7 1.2, n¼ 33; p¼ 0.0039). Both AD-PHP1B and spor-
PHP1B had increased birth weight Z-scores in comparison to the
population of reference (AD-PHP1B 1.2 1.6, n¼ 39; p< 0.0001;
spor-PHP1B 0.5 1.6, n¼ 62; p¼ 0.0172). Overall, 28% of the
AD-PHP1B and 18% of the sporPHP1B cases presented with
macrosomia at birth.
Postnatal growth
We next determined whether postnatal growth was affected
depending on the disease-causing genetic and/or epigenetic
defect at the GNAS locus.
After birth, both PHP1A and PPHP patients displayed a
moderate catch-up growth (Fig. 2A, B) but showed a progressive
decline in growth velocity and lack of pubertal spurt leading to a
ﬁnal short stature (Fig. 2E, F; Fig. 3A) as indicated by the height
Z-scores over time (PHP1A –0.6 1.7 at 3 years, –0.9 1.3 at
10 years, –2.5 1.1 at 18 years; PPHP –1.5 1.5 at 3 years,
–0.2 1.1 at 10 years, –1.9 1.2 at 18 years). Final heights below
the 3rd percentile were found in 64% and in 59% of the PHP1A
(n¼ 84) and PPHP (n¼ 34) patients, respectively (Supplemental
Table S3, Fig. 3A). A similar pattern of longitudinal growth was
observed for girls and boys affected by PHP1A, as shown in
Fig. 2A, B, E, F. For PPHP, we had too few data for male patients
preventing any comparison of sex-speciﬁc growth patterns.
Importantly, we found no inﬂuence of the GNAS genotype (mild
versus severe impact on the Gsa function; exon 1 versus exon
2-13 of Gsa) on birth length and ﬁnal adult heights of PHP1A and
PPHP patients (Table 1, Fig. 3E, Supplemental Fig. S1, Supple-
mental Table S4).
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In contrast to patients with inactivating GNAS mutations,
patients with GNAS methylation defects displayed a pattern of
overgrowth in their ﬁrst years of life (Fig. 2C, D), followed by a
shortened or absent pubertal spurt, leading to a near normal
ﬁnal height (Fig. 2G, H; Fig. 3A). The dramatic increase in growth
velocity was obvious very early in life, as soon as 1 year of age.
Then, we observed a gradual decline of the height Z-scores (AD-
PHP1B 2.2 1.3 at 1 year, 1.2 0.9 at 3 years, –0.2 1.3 at
10 years, and –0.4 1.1 at 18 years; spor-PHP1B 1.3 1.5 at
1 year, 1.1 0.9 at 3 years, 0.8 1.3 at 10 years, and –0.4 1.1 at
18 years). Growth patterns and ﬁnal heights were similar for
males and females (Fig. 2G, H; Fig. 3C).
Postnatal weight gain
We observed an excessive weight gain in all disease subtypes as
shown in Fig. 3B, D, F and Fig. 4.
PHP1A patients showed evidence for early-onset obesity
with a dramatic increase of the BMI Z-score at 1 year of life to
3.5 2.3 (p< 0.0001). Most patients continued to gain weight,
leading by the age of 3 years to a BMI Z-score of 5.0 3.4
(Fig. 4A, B). The ﬁnal BMI Z-score determined at 18 years was
2.2 2.0, including 29/66 patients having a Z-score above 2.
Men and women showed a similar pattern of weight gain;
however, adult PHP1A women were signiﬁcantly heavier than
adult PHP1A men (Z-scores of BMI of 2.6 2.1 [n¼ 41] versus
1.7 1.6 [n¼ 25], p¼ 0.0254), respectively (Fig. 4E, F). Among
adult PHP1A patients, 41% were overweight and 29% were
obese. The weight gain was not inﬂuenced by the GNAS
genotype (Fig. 3F).
Our PPHP cohort was too small to calculate reliable BMI data.
However, we observed that, on average, patients maintained
their BMI above the 50th centile during childhood (Fig. 4A, B, E,
F). The BMI Z-scores of adult PPHP men (0.8 1.8 [n¼ 4]) and
adult PPHP women (1.6 2.8 [n¼ 16]) did not differ signiﬁcantly
(p¼ 0.4458) (Fig. 4E, F).
Interestingly, all patients affected by PHP1B, including AD-
PHP1B and spor-PHP1B, showed a dramatic early-onset weight
gain (Fig. 4C, D, G, H). By the age of 1 year, both AD-PHP1B and
spor-PHP1B patients revealed signiﬁcant overweight with BMI
Z-scores of 2.5 1.6 (n¼ 12) and 2.9 1.4 (n¼ 17), respectively.
Thereafter, themean BMI Z-scores of AD-PHP1B and spor-PHP1B
patients declined progressively and, by adulthood, were still
2.0 2.6 (n¼ 32) and 1.1 1.4 (n¼ 70) above average, respec-
tively. The women, especially affected with spor-PHP1B, were
more overweight than male patients. In fact, the BMI Z-scores of
adult AD-PHP1B and spor-PHP1B women were higher than
those of men (AD-PHP1B women 2.5 3.0 [n¼ 21] versus men
0.9 1.3 [n¼ 11], p¼ 0.1083; spor-PHP1B women 1.6 1.6
[n¼ 37] versus men 0.5 1.0 [n¼ 33], p¼ 0.0020) (Fig. 3D).
Nine percent of the AD-PHP1B and 44% of the spor-PHP1B
women were overweight, and 43% and 13%, respectively,
were obese. In contrast, only 18% of the AD-PHP1B and 27% of
the spor-PHP1B men were overweight, whereas only 9% of the
AD-PHP1B and none of the spor-PHP1B men were obese.
Discussion
The lack of longitudinal data on growth and weight gain of
patients affected with GNAS molecular defects prompted us to
launch a large European and North American collaborative
study, a necessary step to gather large patient cohorts affected
by these rare diseases, and generate comprehensive data. Our
ﬁndings should help to generate hypotheses regarding the
biological roles of the different GNAS-derived transcripts and to
support future guidelines for the management of obesity and
short stature in patients affected by GNAS molecular defects.
Table 1. Birth Length, Birth Weight, Final Height, Weight, and Body Mass Index (BMI) at Age 18 Years in the Different GNAS-Related
Disorders Grouped by Sex or Genotypea
Birth length
(cm) mean (SD; n)
Birth weight
(kg) mean (SD; n)
Final height
(cm) mean (SD; n)
Weight at 18 years
(kg) mean (SD; n)
BMI at 18 years
(kg/m2) mean (SD; n)
PHP1A (iPPSD2)
F n¼ 135 47.1 (2.8; 71) 2.9 (0.6; 85) 146.3 (8.0; 56) 62.2 (15.1; 41) 29.2 (6.2; 42)
M n¼ 107 47.7 (3.8; 72) 3.0 (0.8; 84) 158.1 (6.7; 28) 65.9 (12.6; 26) 26.2 (4.7; 25)
Severe impact n¼ 153 1.1b (1.9; 71) 0.4b (1.7; 85) 2.3b (1.1; 44) 2.0b (1.9; 33)
Mild impact n¼ 79 1.2b (1.6; 44) 0.7b (1.4; 51) 2.6b (1.0; 22) 2.6b (2.2; 16)
Exon 1 n¼ 44 1.3b (0.7; 18) 1.1b (0.8; 23) 2.8b (1.1; 11) 3.1b (2.3; 10)
Exons 2-13 n¼ 189 1.0b (1.9; 126) 0.5b (1.7; 150) 2.4b (1.1; 75) 2.0b (1.8; 39)
PPHP (iPPSD2)
F n¼ 45 43.3 (2.7; 23) 2.1 (0.5; 26) 151.3 (7.8; 28) 59.1 (18.2; 17) 26.0 (8.4; 16)
M n¼ 19 44.4 (3.0; 15) 2.2 (0.5; 16) 159.2 (11.4; 6) 62.0 (15.7; 4) 24.0 (5.0; 4)
Severe impact n¼ 48 3.0b (1.5; 31) 2.6b (1.3; 35) 1.7b (1.3; 23) 0.5b (2.0; 16)
Mild impact n¼ 15 3.1b (1.5; 7) 2.9b (1.4; 7) 2.3b (1.1; 10) 4.3b (1.6; 3)
Exon 1 n¼ 16 2.8b (0.9; 9) 1.9b (0.9; 12) 2.4b (0.9; 8) 0.8b (1.2; 5)
Exons 2-13 n¼ 47 3.1b (1.6; 28) 3.0b (1.3; 29) 1.8b (1.3; 25) 1.2b (2.7; 14)
AD-PHP1B (iPPSD3)
F n¼ 46 50.2 (2.1; 13) 3.7 (0.9; 16) 160.4 (7.4; 24) 72.9 (21.3; 21) 28.8 (8.9; 21)
M n¼ 46 51.2 (2.5; 20) 3.8 (0.5; 23) 172.7 (8.4; 12) 72.7 (13.2; 11) 24.4 (3.7; 11)
spor-PHP1B (iPPSD3)
F n¼ 68 49.4 (2.8; 21) 3.4 (0.7; 28) 160.7 (8.4; 41) 66.7 (12.8; 39) 26.2 (4.7; 37)
M n¼ 60 50.4 (3.5; 24) 3.5 (0.6; 34) 172.0 (6.2; 34) 68.8 (11.3; 33) 25.0 (6.4; 13)
aWHO growth charts do not permit the calculation of weight Z-scores older than age 10 years.
bValues reported as the mean Z-score (SD; n).
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Fig. 2. Longitudinal evolution of length/height depicted for the different disorders. Boys and girls affected with inactivating PTH/PTHrP signaling
disorder or iPPSD2 (PHP1A [red dots and lines] or PPHP [blue dots and lines]) or iPPSD3 (AD-PHP1B [green dots and lines] or spor-PHP1B [black dots and
lines]) are plotted on the WHO growth charts. (A–D) The ﬁrst 3 years of life. (E–H) The pattern of growth from birth to 18 years (adult height). Note the
moderate acceleration of growth in the ﬁrst years of life in iPPSD2, while growth velocity is dramatically increased from birth in iPPSD3.
Fig. 3. Z-scores of adult height and BMI of patients affected with the different GNAS genetic and epigenetic lesions. Raw data (dots), means, and SD
(lines) are presented. (A, B) Comparison of the ﬁnal heights and BMI Z-scores between the different diseases. Statistically different means: p< 0.05;
p< 0.001; p< 0.0001. Note that the scale differs between the panels. (C, D) Data divided according to the sex; (E, F) data divided according to the
genotype of the PHP1A patients.
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Gsa haploinsufficiency and impaired growth
Gsa is biallelically expressed in the growth plate, and it is pivotal
for mediating the actions of the PTH/PTHrP receptor in growth
plate chondrocytes.(22) In humans, monoallelic Gsa expression
appears to cause accelerated chondrocyte differentiation and
premature fusion of the growth plate, ultimately leading to short
stature. An extreme form of accelerated chondrocyte differenti-
ation is also found in mice and humans lacking both copies of
the PTH/PTHrP receptor.(23) In addition, postnatal inactivation of
Gsa in chondrocytes alters the behavior of stem cell-like
chondrocyte located in the resting layer of the growth plate and
leads to a nonexpanding, disorganized cartilage.(24) It is
therefore likely that Gsa haploinsufﬁciency in the growth
plate—and likely other tissues—is responsible for the mild
growth restriction at birth of PHP1A patients and possibly for
the lack of pubertal spurt and consequently for the short stature
identiﬁed in both PHP1A and PPHP patients. In particular, the
impact of Gsa deﬁciency on stem cell-like chondrocytes may
account for an inability to increase growth velocity during
puberty.
Lack of paternal XLas impairs prenatal growth
XLas is a developmentally regulated large Gsa variant that is
expressed only from the paternal GNAS allele in all tissues; its
expression level decreases dramatically after birth.(25) In mice,
germline disruption of Xlas leads to a neonatal phenotype
characterized by thin and narrow bodies and reducedweight.(25)
Our data support the role of XLas for intrauterine growth
because we found severely diminished birth weight and length
in patients affected with paternal GNAS mutations. The
combination of XLas deﬁciency and Gsa haploinsufﬁciency
may explain the severe antenatal growth restriction observed in
PPHP patients, especially in patients with mutations involving
exons 2-13, ie, regions shared between the paternally derived
transcripts for Gsa and XLas.
Reduced maternal Gsa expression contributes to obesity
In contrast to the chondrocyte where Gsa is most likely
expressed from both parental alleles, this signaling protein
appears to be derived in the dorsomedial hypothalamus (DMH),
at least in mice, primarily from the maternal Gnas allele.(26)
Therefore, all maternal GNAS-related disorders likely impair
expression and Gsa-dependent actions at different G-protein
coupled receptors, including MC4R in the DMH.
We have hereby demonstrated that any disease variant
caused by a maternal GNAS molecular defect, ie, PHP1A,
AD-PHP1B, and spor-PHP1B, can be associated with impressive
early-onset obesity. Throughout childhood and in adults,
however, excessive weight gain was more severe and more
frequent in patients affected by PHP1A than by PHP1B. Earlier
studies have suggested that the abnormal weight gain is likely
caused by a defect in the central nervous system rather than in
adipose tissue.(27) In fact, obese children with PHP1A have low
sympathetic nervous system activity, decreased lipolysis,(28) low
metabolic rates, and low resting energy expenditure.(29,30)
Growth hormone deﬁciency due to growth hormone-releasing
hormone resistance in the pituitarymay be another contributing
factor to this central nervous system defect.(31) Thus, a
Fig. 4. Longitudinal evolution of BMI (kg/m2) depicted for the different disorders. Boys and girls affected with iPPSD2 (PHP1A [red dots and lines] or
PPHP [blue dots and lines]) or iPPSD3 (AD-PHP1B [green dots and lines] or spor-PHP1B [black dots and lines]) are plotted on the BMI WHO charts. (A–D)
The ﬁrst 3 years of life. (E–H) The pattern of growth from birth to 18 years (adulthood). Note the dramatic increase in weight gain occurring very early in
life in the four disease variants.
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combination of different tissue-speciﬁc events may contribute
to obesity in PHP1A and PHP1B patients.(27,28,30)
GNAS transcripts and growth evolution
The speciﬁc longitudinal pattern of growth and weight gain in
AD-PHP1B and spor-PHP1B patients, particularly in early life,
could help clarify the relative contribution of the different
GNAS-derived transcripts.
In accordance with our previous ﬁndings in much smaller
cohorts,(15) PHP1B patients, including both AD-PHP1B and spor-
PHP1B, display enhanced fetal growth. This phenotype is even
extended to the ﬁrst years of life. Because of the epigenetic
molecular mechanism that causes PHP1B, it is likely that growth
patterns encountered in PHP1B are, at least in part, controlled by
GNAS-derived transcripts different fromGsa. In patients affected
by spor-PHP1B (note that patients with AD-PHP1B due to
deletions within GNAS are excluded in the herein study because
only a few cases have been described(32)), XLas expression in
growth plates and other tissues is predicted to be biallelic early
in life, thus potentially contributing to our observations of
enhanced growth during fetal life and infancy. However,
patients with AD-PHP1B due to STX16 deletions express XLas
only from their paternal allele, making it unlikely that XLas
contributes to the postnatal overgrowth. In fact, both groups of
patients, AD-PHP1B due to STX16 deletions and spor-PHP1B,
display very similar early overgrowth, followed by a gradual
decline in growth velocity and subsequent normal adult height.
XLas, which is biallelically expressed only in spor-PHP1B
patients, is therefore unlikely to be uniquely responsible for
the overgrowth in all forms of PHP1B. Instead, the A/B transcript
(or another unknown transcript) may contribute through an as-
yet unknown mechanism to the much-enhanced growth. In
addition, we propose that the early-onset obesity, in the context
of open epiphyses, combined with biallelic expression of Gsa in
chondrocytes, is likely a major driver of the enhanced growth in
these patients.
Alternate GNAS-derived transcripts have distinct roles
during pubertal development
The cause of the insufﬁcient pubertal spurt in the different
disease variant remains to be investigated. Affected patients
may present with lower Gsa expression in stem cell-like
chondrocytes, which could impede the increase in growth
velocity during puberty.(33) Interestingly, XLas appears to have
no major role in postnatal growth plates as indicated by mice
with ablation of Gnas exon 1 from the paternal allele, thus
lacking paternal Gsa but not Xlas.(24) This is concordant with our
observations in PPHP patients with paternal GNAS mutations
involving exons 2-13, ie, lacking XLas and paternal Gsa, who
display a severe antenatal growth restriction yet postnatal and
adult heights that are similar to those in PHP1A patients bearing
maternal GNAS exons 2-13 mutations.
In addition, obesity may accelerate the bone maturation, as
commonly observed.(34) Furthermore, some patients may show
early pubertal development or early adrenarche, in the context
of advanced bone age, as observed in other imprinting
disorders.(35)
Limitations of our studies
Weaknesses of our study include the lack of parental heights,
heights of healthy siblings, age at puberty and menarche, and
additional data such as age at diagnosis and thyroid or growth
hormone status, which could help elucidate further the
mechanisms underlying growth and weight gain in
GNAS-related disorders. To better understand the underlying
determinants of growth, weight gain, and puberty, including the
sex differences, prospective studies and follow-up need to be
pursued in patients affected by the different GNAS-related
disorders.
Conclusions
From our observations, we conclude that 1) for the majority of
PHP1A and PPHP patients, ie, patients carrying a GNAS loss-of-
functionmutation, normal length/height during childhood does
not predict a normal adult height as short stature becomes
apparent only gradually in these disorders; 2) close follow-up of
growth, pubertal development, and bone maturation is
recommended by mid childhood, especially for patients with
inactivating GNAS mutations; 3) the maternal mutations or
methylation defects of GNAS, as in patients affected with PHP1A,
AD-PHP1B, and spor-PHP1B, can cause impressive early-onset
obesity that persists through adulthood, especially in women;
speciﬁc interventions should therefore be instated as soon as
the diagnosis is made to limit obesity, thus long-term metabolic
consequences; 4) large collaborative studies are of major
importance to gather representative data for these rare diseases
and to better understand the impact of GNAS imprinting on
major development processes, including growth, fat storage,
and pubertal development.
Disclosures
AL received a research grant for the investigator-initiated study
from IPSEN (#8NL7). All other authors state that they have no
conﬂicts of interest.
Acknowledgments
We are very grateful to the Spanish patient association
(Asociacion Espa~nola de PHP, AEPHP), the patients, and their
families for their contribution to the study. We thank Luigi Di
Nicola for his support for the Ipsen external-sponsored study.
Thisworkwas supportedby recurrent INSERMfunding (toAL), an
external-sponsored study research grant from Ipsen (#8NL7 to AL),
a crowdfunding project precipita.es (FECYT, MINECO to GPdN),
National Institutes of Health grants (RO1 DK46718 and PO1
DK11794, subproject 4, to HJ and K23 DK101689 to AS), a grant
from the Instituto de Salud Carlos III (Institute of Health Carlos III) of
theMinistryof EconomyandCompetitiveness (Spain) (toGPdNand
AP), co-ﬁnanced by the European Regional Development Fund
(PI16-00073), a grant from the Department of Health of the Basque
Government (GV2016/111105 to JE), a grant from the French
Society of Pediatric Endocrinology and Diabetology (SFEDP) and
Sandoz (to VG), a grant from the SFEDP and Pﬁzer (to PH), and a
grant from theSFEDPandLilly (to LCT). The funding sourceshadno
roles regarding the study or the publication.
Authors’ roles: PH, VG, GPdN, GM, and AL conducted the
study. GPdN, LdS, PK, AR, ST, AS, MLK, HJ, GM, and AL recruited
patients. All authors collected data. PH, GPdN, HJ, GM, and AL
analyzed the results and wrote the ﬁrst and revised versions of
the manuscript. All authors contributed to the writing and
edition of the manuscript. AL, as corresponding author,
endorses responsibility for the integrity of the data analysis.
Journal of Bone and Mineral Research DISTINCT PATTERNS OF FETAL AND POSTNATAL GROWTH IN GNAS-RELATED DISORDERS 1487
References
1. Albright F, Burnett CH, Smith PH, Parson W. Pseudohypoparathyr-
oidism — an example of “Seabright-Bantam syndrome.”
Endocrinology. 1942;30:922–32.
2. Mantovani G, Spada A, Elli FM. Pseudohypoparathyroidism and Gsa-
cAMP-linked disorders: current view and open issues. Nat Rev
Endocrinol. 2016;12(6):347–56.
3. Hayward BE, Moran V, Strain L, Bonthron DT. Bidirectional imprinting
of a single gene: GNAS1 encodes maternally, paternally, and
biallelically derived proteins. Proc Natl Acad Sci USA. 1998;95(26):
15475–80.
4. Yu S, Yu D, Lee E, et al. Variable and tissue-speciﬁc hormone
resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha)
knockout mice is due to tissue-speciﬁc imprinting of the gsalpha
gene. Proc Natl Acad Sci USA. 1998;95(15):8715–20.
5. Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A. The
gsalpha gene: predominant maternal origin of transcription in
human thyroid gland and gonads. J Clin Endocrinol Metab.
2002;87(10):4736–40.
6. Weinstein LS, Gejman PV, Friedman E, et al. Mutations of the Gs
alpha-subunit gene in Albright hereditary osteodystrophy detected
by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA.
1990;87(21):8287–90.
7. Liu J, Litman D, Rosenberg MJ, Yu S, Biesecker LG, Weinstein LS.
A GNAS1 imprinting defect in pseudohypoparathyroidism type IB.
J Clin Invest. 2000;106(9):1167–74.
8. Elli FM, Linglart A, Garin I, et al. The prevalence of GNAS deﬁciency-
related diseases in a large cohort of patients characterized by the
EuroPHP network. J Clin Endocrinol Metab. 2016;101(10):3657–68.
9. Fernandez-Rebollo E, Lecumberri B, Garin I, et al. New mechanisms
involved in paternal 20q disomy associated with pseudohypopar-
athyroidism. Eur J Endocrinol Eur Fed Endocr Soc. 2010;163(6):953–62.
10. Mantovani G, de Sanctis L, Barbieri AM, et al. Pseudohypoparathyr-
oidism and GNAS epigenetic defects: clinical evaluation of albright
hereditary osteodystrophy and molecular analysis in 40 patients.
J Clin Endocrinol Metab. 2010;95(2):651–8.
11. Thiele S, Mantovani G, Barlier A, et al. From pseudohypoparathyr-
oidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel
classiﬁcation proposed by the EuroPHP network. Eur J Endocrinol.
2016;175(6):P1–17.
12. Linglart A, Carel JC, Garabedian M, Le T, Mallet E, Kottler ML. GNAS1
lesions in pseudohypoparathyroidism Ia and Ic: genotype pheno-
type relationship and evidence of the maternal transmission of the
hormonal resistance. J Clin Endocrinol Metab. 2002;87(1):189–97.
13. Long DN, McGuire S, Levine MA, Weinstein LS, Germain-Lee EL. Body
mass index differences in pseudohypoparathyroidism type 1a
versus pseudopseudohypoparathyroidism may implicate paternal
imprinting of Galpha(s) in the development of human obesity. J Clin
Endocrinol Metab. 2007;92(3):1073–9.
14. Richard N, Molin A, Coudray N, Rault-Guillaume P, J€uppner H, Kottler
M-L. Paternal GNAS mutations lead to severe intrauterine growth
retardation (IUGR) and provide evidence for a role of XLas in fetal
development. J Clin Endocrinol Metab. 2013;98(9):E1549–56.
15. Brehin A-C, Colson C, Maupetit-Mehouas S, et al. Loss of methylation
at GNAS exon A/B is associated with increased intrauterine growth.
J Clin Endocrinol Metab. 2015;100(4):E623–31.
16. Gr€uters-Kieslich A, Reyes M, Sharma A, et al. Early-onset obesity:
unrecognized ﬁrst evidence for GNAS mutations and methylation
changes. J Clin Endocrinol Metab. 2017;102(8):2670–7.
17. Romanet P, Osei L, Netchine I, et al. Case report of GNAS epigenetic
defect revealed by a congenital hypothyroidism. Pediatrics.
2015;135(4):e1079–83.
18. WHO. The WHO child growth standards [Internet]. WHO. Accessed
2017 Oct 26. Available at: http://www.who.int/childgrowth/stand
ards/en/.
19. Mamelle N, Cochet V, Claris O. Deﬁnition of fetal growth restriction
according to constitutional growth potential. Biol Neonate.
2001;80(4):277–85.
20. Turan S, Thiele S, Tafaj O, et al. Evidence of hormone resistance in a
pseudo-pseudohypoparathyroidism patient with a novel paternal
mutation in GNAS. Bone. 2015;71:53–7.
21. Garin I, Mantovani G, Aguirre U, et al. European guidance for the
molecular diagnosis of pseudohypoparathyroidism not caused by
point genetic variants at GNAS: an EQA study. Eur J Hum Genet.
2015;23(4):438–44.
22. Bastepe M, Weinstein LS, Ogata N, et al. Stimulatory G protein
directly regulates hypertrophic differentiation of growth plate
cartilage in vivo. Proc Natl Acad Sci U S A. 2004;101(41):14794–9.
23. Kronenberg HM. PTHrP and skeletal development. Ann NY Acad Sci.
2006;1068:1–13.
24. Chagin AS, Vuppalapati KK, Kobayashi T, et al. G-protein stimulatory
subunit alpha and Gq/11a G-proteins are both required to maintain
quiescent stem-like chondrocytes. Nat Commun. 2014;5:3673.
25. Plagge A, Gordon E, Dean W, et al. The imprinted signaling protein
XL alpha s is required for postnatal adaptation to feeding. Nat Genet.
2004;36(8):818–26.
26. Chen M, Shrestha YB, Podyma B, et al. Gsa deﬁciency in the
dorsomedial hypothalamus underlies obesity associated with Gsa
mutations. J Clin Invest. 2017;127(2):500–10.
27. Chen M, Berger A, Kablan A, Zhang J, Gavrilova O, Weinstein LS. Gsa
deﬁciency in the paraventricular nucleus of the hypothalamus
partially contributes to obesity associated with Gsa mutations.
Endocrinology. 2012;153(9):4256–65.
28. Carel JC, Le Stunff C, Condamine L, et al. Resistance to the lipolytic
action of epinephrine: a new feature of protein Gs deﬁciency. J Clin
Endocrinol Metab. 1999;84(11):4127–31.
29. Shoemaker AH, Lomenick JP, Saville BR, Wang W, Buchowski MS,
Cone RD. Energy expenditure in obese children with pseudohypo-
parathyroidism type 1a. Int J Obes. (Lond). 2013;37(8):1147–53.
30. Roizen JD, Danzig J, Groleau V, et al. Resting energy expenditure is
decreased in pseudohypoparathyroidism type 1A. J Clin Endocrinol
Metab. 2016;101(3):880–8.
31. Mantovani G, MaghnieM,Weber G, et al. Growth hormone-releasing
hormone resistance in pseudohypoparathyroidism type 1a: new
evidence for imprinting of the Gs alpha gene. J Clin Endocrinol
Metab. 2003;88(9):4070–4.
32. Bastepe M, Fr€ohlich LF, Linglart A, et al. Deletion of the NESP55
differentially methylated region causes loss of maternal GNAS
imprints and pseudohypoparathyroidism type Ib. Nat Genet.
2005;37(1):25–7.
33. Zazo C, Thiele S, Martın C, et al. Gsa activity is reduced in erythrocyte
membranes of patients with pseudohypoparathyroidism due to
epigenetic alterations at the GNAS locus. J Bone Miner Res. 2011;26
(8):1864–70.
34. Shalitin S, Kiess W. Putative effects of obesity on linear growth and
puberty. Horm Res Paediatr. 2017;88(1):101–10.
35. Soellner L, Begemann M, Mackay DJG, et al. Recent advances in
imprinting disorders. Clin Genet. 2017;91(1):3–13.
1488 HANNA ET AL. Journal of Bone and Mineral Research
